Lexicon Pharmaceuticals,
Inc. LXRX announced that data from the Phase 2b clinical trial of
LX4211 are being presented today as a Clinical Sciences Special Report in the
Emerging Therapeutics for Diabetes and Dyslipidemia section of the American
Heart Association (AHA) Scientific Sessions Conference held in Los Angeles,
California. The oral presentation is being delivered by Dr. Julio Rosenstock,
Director of the Dallas Diabetes and Endocrine Center at Medical City, lead
investigator in the recently completed study.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in